KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Non Operating Income (2018 - 2025)

Moderna (MRNA) has disclosed Non Operating Income for 8 consecutive years, with -$12.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income rose 58.62% to -$12.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$8.0 million, a 90.8% increase, with the full-year FY2025 number at -$8.0 million, up 90.8% from a year prior.
  • Non Operating Income was -$12.0 million for Q4 2025 at Moderna, down from $8.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $14.0 million in Q2 2023 to a low of -$51.0 million in Q3 2023.
  • A 5-year average of -$15.4 million and a median of -$12.0 million in 2022 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: tumbled 900.0% in 2021, then soared 207.69% in 2023.
  • Moderna's Non Operating Income stood at -$7.0 million in 2021, then crashed by 71.43% to -$12.0 million in 2022, then tumbled by 225.0% to -$39.0 million in 2023, then increased by 25.64% to -$29.0 million in 2024, then skyrocketed by 58.62% to -$12.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Non Operating Income are -$12.0 million (Q4 2025), $8.0 million (Q2 2025), and -$4.0 million (Q1 2025).